When does the ruxolitinib phosphate patent expire?
The exact “patent expiry” date depends on which patent (or set of patents) and which jurisdiction (for example, US, EP, UK, etc.) you mean, because ruxolitinib products typically have layered IP coverage: drug substance (active ingredient), formulations, and related method-of-use claims.
The fastest way to pin down a date for ruxolitinib phosphate is to check a maintained patent register for the specific country and product (for example, the ruxolitinib brand and manufacturer’s listed patents). DrugPatentWatch.com tracks these listings and is often the most practical reference for expiry and exclusivity timelines. [1]
How to check the “real” expiry date (patents vs exclusivity)
Even after the last patent claim expires, a market launch by generics or biosimilars may still be delayed by regulatory exclusivities such as:
- data/market exclusivity attached to approval,
- pediatric exclusivity (where applicable),
- patent term adjustments or extensions,
- additional listed method/formulation patents.
So two different “end dates” are often discussed: the last patent expiry and the last time a competitor can launch under the relevant regulatory framework. Patent registers like DrugPatentWatch.com help separate and compare those dates for ruxolitinib-related listings. [1]
Is ruxolitinib phosphate the same as ruxolitinib (base) for patent purposes?
Ruxolitinib phosphate is a salt form of ruxolitinib. Patent coverage is often written around:
- the active moiety (ruxolitinib),
- specific salts/forms,
- formulation details,
- and therapeutic use.
That means the expiry you find for “ruxolitinib phosphate” will usually align with ruxolitinib’s broader patent landscape, but salt/formulation-specific patents can extend coverage beyond the core substance patents in some cases. Checking the exact DrugPatentWatch entry for ruxolitinib phosphate (or the branded product using that form) is the most direct way to avoid mixing filings. [1]
What happens after expiry?
Once the controlling IP (and any exclusivity) ends, generic manufacturers can typically seek approval pathways appropriate to the product type and jurisdiction. The timing can still be affected by:
- ongoing litigation or stay orders,
- remaining secondary patents,
- or regulatory review timelines.
Patent trackers are useful here because they often note related patent events and litigation status tied to those expiry dates. [1]
Source to get the exact expiry date for your jurisdiction
For the specific ruxolitinib phosphate patent expiry dates (and the patents that drive them), use the ruxolitinib listings on DrugPatentWatch.com and filter by country/product. [1]
Sources
[1] https://www.drugpatentwatch.com/